ASX:LGI
ASX:LGIRenewable Energy

ASX Stocks Estimated To Be Up To 48.3% Below Intrinsic Value

In the current Australian market landscape, recent events such as the Reserve Bank of Australia's decision to hold interest rates steady have led to mixed reactions, with major indices experiencing fluctuations and sectors like real estate showing some resilience. Amidst these conditions, identifying undervalued stocks can be a strategic approach for investors seeking opportunities that may offer potential upside when market sentiments shift.
ASX:ARX
ASX:ARXBiotechs

ASX Penny Stocks Under A$900M Market Cap To Watch

The Australian market recently experienced a brief surge following the Reserve Bank of Australia's decision to hold interest rates steady, though it settled into a slightly negative territory by the day's end. In such fluctuating conditions, identifying promising investments requires a keen eye for companies with strong financial foundations. Penny stocks, although an older term, remain relevant as they often represent smaller or newer companies that can offer unique opportunities for growth...
ASX:AYA
ASX:AYAHealthcare Services

Assessing Artrya (ASX:AYA)’s Valuation After Its New Three-Year U.S. Hospital Agreement

Artrya (ASX:AYA) has secured a three year commercial agreement to deploy its Salix platform across Northeast Georgia Health System, providing at least A$300,000 in revenue with additional potential from per scan fees. See our latest analysis for Artrya. The announcement appears to have accelerated an already powerful trend, with a 7 day share price return of 25.56 percent contributing to a 533.87 percent year to date share price return and a 727.37 percent 1 year total shareholder return...
ASX:CUV
ASX:CUVBiotechs

Is Clinuvel (ASX:CUV) Using Its Singapore Peptide Hub To Quietly Redefine Its Pipeline Ambitions?

Clinuvel Pharmaceuticals has recently expanded its Vallaurix research, development, and innovation hub in Singapore, backed by the Singapore Economic Development Board, to build a global center for advanced, long-acting peptide therapies and integrated formulation and analytical sciences. This move strengthens Clinuvel’s push toward greater vertical integration in peptide-based medicine, aiming to speed up late-stage development programs and broaden its pipeline beyond a single flagship...
ASX:SEC
ASX:SECCapital Markets

ASX Penny Stocks To Watch In December 2025

With the Reserve Bank of Australia expected to maintain its current interest rate, Australian shares are experiencing another dip, influenced by overnight declines in major U.S. indices. Despite these broader market movements, opportunities still exist within specific sectors and stocks. Penny stocks—once a buzzword but now more of a niche—continue to offer growth potential by providing access to smaller or newer companies that may possess strong financial health and long-term prospects.
ASX:WAT
ASX:WATLeisure

Top ASX Dividend Stocks To Consider In December 2025

As the Australian market navigates a cautious landscape, with telecoms leading amidst broader sector declines and rate pause expectations from the RBA, investors are keenly observing how these dynamics might influence dividend stocks. In such an environment, selecting robust dividend stocks involves looking for companies with strong fundamentals and consistent payout histories to potentially weather economic fluctuations.
ASX:PCL
ASX:PCLOil and Gas

Bass Oil And 2 Other ASX Penny Stocks To Consider

As the Australian market navigates a period of uncertainty, with telecoms leading and materials facing challenges, investors are keenly watching economic indicators like the RBA's rate decisions. In this context, penny stocks—though considered a niche area—remain an intriguing option for those looking to uncover potential growth opportunities in smaller or newer companies. These stocks can offer significant returns when backed by strong financial health, and we will explore three such...
ASX:PMV
ASX:PMVSpecialty Retail

Premier Investments (ASX:PMV) Valuation After A$100m Buyback And Softer First-Half Earnings Outlook

Premier Investments (ASX:PMV) has put a A$100 million on market share buyback on the table just as it guides to weaker first half earnings, a combination that is getting investors attention. See our latest analysis for Premier Investments. The new buyback lands after a bruising stretch for investors, with Premier’s share price down sharply year to date and over the past quarter, even as its five year total shareholder return remains positive and recent earnings guidance has cooled...